This live satellite symposium uses an interactive, case-based Q Challenge format with audience polling to examine treatment decisions in post-platinum extensive-stage small-cell lung cancer (ES-SCLC). Through clinical case scenarios, expert faculty discuss B7-H3 directed antibody-drug conjugate (ADC) evidence. They ll cover patient eligibility, treatment selection, CNS activity, and sequencing considerations in the context of other second-line options such as a bispecific delta-like ligand 3 (DLL3) directed CD3 T cell engagers. Clinical cases also focus on treatment-emergent interstitial lung disease (ILD), addressing recognition, differential diagnosis, grading, monitoring, corticosteroid management, and coordination between oncology and pulmonology. Through expert commentary and decision-making checkpoints, the activity applies clinical trial data and toxicity-management guidance to real-world patient selection and multidisciplinary care.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
CME included with membership
| Free Registration | Free |
| Tufts-Affiliated HCP - Early Bird (by 10/5/26) | $75 |
| Tufts-Affiliated HCP - Standard | $175 |
| Trainees & Allied Health - Early Bird (by 10/5/26) | $75 |
| Trainees & Allied Health - Standard | $175 |
| Physicians - Early Bird (by 10/5/26) | $150 |
+3 more tiers
Collected from the provider’s public pages · source
Specialties served/covered
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- General & Adult Psychiatry
- General Pediatrics
- Gynecologic Oncology
- Head & Neck Surgery
- Hematology
- Maternal-Fetal Medicine
- Medical Genetics & Genomics
- Medical Oncology
- Mood & Anxiety Disorders
- Nephrology
- Neurology
- Neuromuscular Medicine
- Neuroradiology
- Obstetrics & Gynecology
- Ophthalmology
- Pediatric Neurology
- Psychopharmacology
- Psychotic Disorders
- Pulmonary Disease
- Radiation Oncology
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Transplant Hepatology
- Urological Oncology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Conference / congress
- Credit · Up to 1 credit
- Commercial Support
-
WhenDec 5, 2026
-
Answers in CME Inc. (AiCME) New Frontiers in Small Cell Lung Cancer: Getting Ready for the Emergence of B7-H3 Directed ADCs
-
PRIME Education, Inc. (PRIME®) The Latest Clinical Evidence for Antibody-Drug Conjugates in ES-SCLC
-
Clinical Care Options, LLC (dba Decera Clinical Education) HER2- and TROP2-Directed ADCs in NSCLC: Patient Selection, Treatment Sequencing, and Toxicity Management in a Rapidly Evolving Landscape
-
Global Learning Collaborative Beyond Checkpoint Blockade in SCLC: Emerging Antigen Targets and Treatment Strategies Across Disease Stages
-
Global Learning Collaborative Redefining First-Line Therapy of Metastatic TNBC: Integrating TROP2-Directed ADCs Into Modern Treatment Strategy
-
Global Learning Collaborative Chairman’s Perspective: TROP2-Targeted ADCs in TNBC and HR+ mBC
